"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 7 | 1 | 8 |
| 1995 | 13 | 3 | 16 |
| 1996 | 14 | 5 | 19 |
| 1997 | 14 | 2 | 16 |
| 1998 | 27 | 5 | 32 |
| 1999 | 19 | 3 | 22 |
| 2000 | 17 | 4 | 21 |
| 2001 | 36 | 1 | 37 |
| 2002 | 40 | 5 | 45 |
| 2003 | 62 | 6 | 68 |
| 2004 | 53 | 4 | 57 |
| 2005 | 87 | 7 | 94 |
| 2006 | 72 | 5 | 77 |
| 2007 | 89 | 10 | 99 |
| 2008 | 86 | 11 | 97 |
| 2009 | 96 | 10 | 106 |
| 2010 | 93 | 11 | 104 |
| 2011 | 107 | 13 | 120 |
| 2012 | 117 | 8 | 125 |
| 2013 | 99 | 10 | 109 |
| 2014 | 109 | 6 | 115 |
| 2015 | 103 | 6 | 109 |
| 2016 | 105 | 9 | 114 |
| 2017 | 104 | 5 | 109 |
| 2018 | 95 | 12 | 107 |
| 2019 | 106 | 6 | 112 |
| 2020 | 108 | 4 | 112 |
| 2021 | 102 | 3 | 105 |
| 2022 | 106 | 0 | 106 |
| 2023 | 93 | 3 | 96 |
| 2024 | 102 | 5 | 107 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study. Clin Cancer Res. 2024 Dec 16; 30(24):5559-5567.
-
Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas. Gut. 2024 Dec 10; 74(1):75-88.
-
Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Examining the effects of biofield therapy through simultaneous assessment of electrophysiological and cellular outcomes. Sci Rep. 2024 12 02; 14(1):29221.
-
Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication. JAMA Surg. 2024 Dec 01; 159(12):1365-1373.
-
Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024 Nov 22; 45(11):836-844.
-
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. Gut. 2024 Nov 11; 73(12):1984-1998.
-
DNA methylation classifier to diagnose pancreatic ductal adenocarcinoma metastases from different anatomical sites. Clin Epigenetics. 2024 Nov 10; 16(1):156.
-
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Pancreatic Cancer-Associated Fibroblasts: Where Do We Go from Here? Cancer Res. 2024 Nov 04; 84(21):3505-3508.